Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexketamine and post-reperfusion syndrome in pediatric living-donor liver transplantation
ChiCTR2200057410Phase 4Not yet recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of esketamine in Post-reperfusion syndrome (PRS) (2 arms), sponsored by Tianjin First Central Hospital. Primary endpoint: Incidence of post-reperfusion syndrome. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
Post-reperfusion syndrome (PRS)
Beyond the preview
Go deeper on ChiCTR2200057410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057410.